Weekly Assessment of the therapeutic efficacy of different doses of Eprex on RBCs indices and managing of anemia in chronic kidney disease adult patients
Abdulmalik Alkatheri, Abdelkareem Albekairy, Yousef Al-Rajhi, Rami Bustami and Mahmoud Mansour
King Saud Bin Abdulaziz University for Health Sciences, Saudi Arabia
: J Clin Exp Dermatol Res
Treatment with lower dose of DA (0.64±0.07 μg/kg QW) induced a significant increase in hemoglobin (HB) from week 4 through week 8, while red blood corpuscles (RBCs) and hematocrit (Hct) were significantly elevated in week 8. A significant increase in HB and Hct were observed starting from week 2 through week 8 parallel with a significant rise in RBCs count, starting from week 3 through week 8 after treatment with DA (0.8±0.06 μg/kg QW), while a significant increment of HB and Hct were noticed after treatment with DA (1.215±0.11 μg/kg QW) from week 3 to week 7. Administration of higher dose DA (1.37±0.22 μg/kg QW) led to a significant rise of RBCs in week 3, 6 and 7 while HB and Hct in week 6 and 7. Treatment with equal doses of Eprex (170.85±16.4 IU/kg and 238±25.9 IU/kg) induced only a mild increase in RBCs in week 7 and 6 respectively, while higher dose of Eprex (413±40.8 IU/kg) elevated RBCs significantly at week 8 and Hct in week 6 and 8. Administration of DA QW is more effective than Eprex QTIW in terms of target anemia parameters: RBCs, HB and Hct during the first 8 weeks of administration.
E-mail: [email protected]